Bioventus Net Income

The latest net income for BVS is $57M as of September 2026. That compares with $7.8M in the prior-year period — up 632.6% year over year. That is below the Healthcare sector average of $1.5T. Investors often review this figure alongside Bioventus's historical trend and sector peers before judging valuation or financial health.

Over the past year, BVS's net income moved from $7.8M to $57M — a 632.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioventus's operating scale or balance-sheet position.

Against Healthcare companies, BVS currently prints $57M for net income, while the sector average sits near $1.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Bioventus's growth, margins, and balance sheet.

A net income figure of $57M for BVS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.5T. Explore the charts below for those layers of context.

After noting BVS's net income ($57M), review year-over-year change from $7.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.